Abstract

RADIOBIOLOGYANDRADIOTHERAPYRESEARCHPROGRAM PROGRAMCODE:RR PROGRAMSUMMARY/ABSTRACT TheRadiobiology&Radiotherapy(RR)ResearchProgramcomprisesabroadlybased,multifacetedresearch effortinradiationtherapy,radiationbiology,radiologicalphysics,andrelatedareasoftumorbiology,including amajoreffortinDNAdamageandrepair.Itslong-termgoalistoimprovethetreatmentofcanceringeneral andtheeffectivenessofradiationtherapyinparticular.
The SpecificAims oftheprogramaretoelucidate pathwaysofcancerbiologythatimpactradiationtherapyandtoconductclinicalandtranslationalresearch aimedatimprovingradiationtherapy.Theprogramincludesabroadspectrumofactivitythatextendsfrom laboratory-basedexperimentalresearchtoclinicalinvestigation,anditfeatures36investigatorswithinten departments.Keythemesincludestudiesof:1)carcinogenesis,geneticinstability,andcellgrowthcontrol;?2) elucidationofDNArepairpathways,andinvestigationoftumorhypoxiaandtheimpactofhypoxiaoncancer therapy;?3)preclinicaldevelopmentofradiationsensitizersandDNArepairinhibitors,includingcombinationof DNArepairinhibitorswithimmunetherapy;?4)molecularcorrelationswithoutcomesinradiationtherapy;?5) healthservicesanddisparitiesresearchinradiationoncology;?6)designandconductofclinicaltrialsrelevant toradiationoncology;?and7)improvementsinradiationdosimetry,imaging,anddelivery.Mostprogram memberscollaborateactivelywithinvestigatorsinotherYCCprograms,and34%ofthe555RRpublicationsin thepastfundingperiodrepresentinter-programmaticcollaborations.Thesecollaborativeinteractionsstimulate translationalresearchthatisfacilitatedbyextensiveuseofsharedresources.Thenumerouscancer-related grandrounds,seminars,meetings,andjournalclubssponsoredbyYCC,alongwiththeweeklyRadiobiology WorkshopandTherapeuticRadiologyGrandRoundssponsoredbytheprogram,encouragecooperation, mutualsupport,andcross-stimulationamongresearchteams,whichleadstomorerapidandefficient applicationofresearchresultstoclinicalpractice.TheprogramleadersareDr.PeterM.GlazerandDr.Joann Sweasy.Dr.Glazertookoverasleaderin2002,replacingDr.JamesJ.Fischer,whohadservedasprogram leadersinceitsinception.Inthepastfundingperiod,Dr.JoannSweasywasnamedco-leader.TogetherDrs. GlazerandSweasyhaverecruitedseveralbasicscientistsandphysicianinvestigatorstotheCancerCenter. Theprogramalsohascompletedrenovationof15,500ft2 oflaboratoryspace,partiallyfundedbya$2million constructiongrantfromtheNIH.Dr.Glazeralsoservesasco-PI(withDavidStern,ST)ofaT32pre-and postdoctoraltraininggrantincancerbiology,whichincludesfacultydrawnfromRR,ST,andotherYCC programs.AsofJune1,2017,the36programinvestigatorshavepeer-reviewedfundingof$5.7Minannual directcosts,including18R01s.Ofthisfunding,$3.6M(annualdirectcosts)comesfromtheNCI,including12 R01sandtwoR21s.Thisrepresentsa55%increaseinpeer-reviewedcancerfundinganda138% increaseinNCIfundingsincethelastrenewal.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-41
Application #
9989600
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
41
Fiscal Year
2020
Total Cost
Indirect Cost

  Institution

Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520

  Publications

Chae, Wook-Jin; Bothwell, Alfred L M (2018) Therapeutic Potential of Gene-Modified Regulatory T Cells: From Bench to Bedside. Front Immunol 9:303
Kim, Hanseul; Keum, NaNa; Giovannucci, Edward L et al. (2018) Garlic intake and gastric cancer risk: Results from two large prospective US cohort studies. Int J Cancer 143:1047-1053
Sarma, Elizabeth A; Kawachi, Ichiro; Poole, Elizabeth M et al. (2018) Social integration and survival after diagnosis of colorectal cancer. Cancer 124:833-840
Hartman, Douglas J; Ahmad, Fahad; Ferris, Robert L et al. (2018) Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. Oral Oncol 86:278-287
Chen, Ling; Azuma, Takeshi; Yu, Weiwei et al. (2018) B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction. Proc Natl Acad Sci U S A 115:3126-3131
Zhang, Jinhua; Song, Kun; Wang, Jun et al. (2018) S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity. Oncoimmunology 7:e1296996
Kelada, Olivia J; Decker, Roy H; Nath, Sameer K et al. (2018) High Single Doses of Radiation May Induce Elevated Levels of Hypoxia in Early-Stage Non-Small Cell Lung Cancer Tumors. Int J Radiat Oncol Biol Phys 102:174-183
Powles, Ryan L; Redmond, David; Sotiriou, Christos et al. (2018) Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 4:e181564
Wang, Shi-Yi; Hsu, Sylvia H; Huang, Siwan et al. (2018) Regional Practice Patterns and Racial/Ethnic Differences in Intensity of End-of-Life Care. Health Serv Res 53:4291-4309
Gettinger, S N; Choi, J; Mani, N et al. (2018) A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nat Commun 9:3196

Showing the most recent 10 out of 675 publications